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SUMMARY – Epithelioid hemangioendothelioma is a rare vascular brain tumor. It develops 
from endothelial cells, usually in the liver, lung, bone and soft tissue. Primary localization of this tumor 
in the intracranial space is very uncommon; only 47 cases have been described in the literature. Th is 
tumor was initially classifi ed as grade I (benign) in the World Health Organization (WHO) 2007 
classifi cation. In 2016, this tumor was re-classifi ed as grade III (malignant). Herein, the fi rst case 
 report of epithelioid hemangioendothelioma in the cerebellum of a male patient is presented. 
 Complete surgical excision was done. No adjuvant therapy was administered. Magnetic resonance 
imaging performed 2 years after the surgery continued to show no recurrence of the tumor. To our 
knowledge, this is the fi rst report of cerebellar location of this rare tumor. In addition, the authors 
report drastic re-classifi cation of the epithelioid hemangioendothelioma from the benign tumor 
(WHO 2007) to a malignant one (2016), which signifi cantly changes postoperative management and 
follow up of this brain neoplasm.
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Introduction
Epithelioid hemangioendothelioma (EHE) is a 
rare and uncommon vascular tumor of the brain1,2. 
Malignant characteristics of EHE are invasion, recur-
rence and metastasis, and these characteristics are 
more pronounced in the intracranial space. It accounts 
for less than 0.02% of all brain tumors. Only 47 cases 
of this tumor have been reported intracranially, with 
only 6 cases in the posterior cranial fossa, outside of 
the cerebellum (two in pediatric population). None of 
the posterior fossa cases was totally removed; fi ve had 
subtotal resection and one only biopsy. No primary lo-
calization of EHE in the cerebellum has been reported 
so far3.
In this case report, the authors describe the fi rst 
EHE of cerebellar location with radical tumor resec-
tion. In addition, we report drastic change in the clas-
sifi cation of this tumor from benign (World Health 
I. Omerhodžić et al. Epithelioid hemangioendothelioma in the cerebellum
Acta Clin Croat, Vol. 57, No. 3, 2018 571
Organization (WHO) classifi cation 2007) to malig-
nant (WHO classifi cation 2016).
Case Report
A 34-year-old male patient was admitted to the 
University Clinical Center of Sarajevo with a 20-day 
history of progressive headache and vomiting. Th e pa-
tient reported fatigue, weight loss in the past month 
and vertigo. Examination showed gait diffi  culties due 
to vertigo and fatigue. Physical and neurological ex-
amination was normal without nuchal rigidity. Non-
contrast magnetic resonance imaging (MRI) of the 
brain visualized an irregular heterogeneous signal in-
Fig. 1. Preoperative MRI. Axial and sagittal scans showing a tumor mass in the cerebellum only partially involving the 
brain stem: (a) axial post-contrast T1; (b) axial T2; (c) sagittal post-contrast T1; (d) sagittal T2 MRI images.
Fig. 2. MRI scans at three months postoperatively showing completely resected tumor: (a) axial T1; 
(b) axial post-contrast T1; (c) sagittal contrast T1; (d) sagittal non-contrast T1 MRI images.
Fig. 3. Postoperative MRI (2 years) showing no reccurence of the tumor; (a) axial post-contrast T1; 
(b) axial non-contrast T1; (c) sagittal post-contrast T1; (d) axial T2 MRI images.
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tensity area in the midline within the cerebellum, 
compressing the fourth ventricle and propagating to-
wards the brain stem at the level of medulla oblongata 
and parasagittal left side of the pons. Within this zone, 
there was an area of T1 hyperintensities, and several 
T2 marginally hypointense areas representing proba-
ble hemorrhages. Post-contrast MRI showed occa-
sional opacifi cation. Th e size of the lesion measured 
38x44x37 mm (Fig. 1).
Th e patient underwent surgery in prone position 
the next day after admission. Median suboccipital cra-
niotomy was performed, followed by telovelar micro-
surgical approach. Th e tumor appearance was gray-
blue, and it was highly vascular, with hard and soft 
parts. Th e usual microsurgical technique with gross 
total tumor resection was employed. After tumor re-
moval, hemostasis was performed, dura mater was 
closed in watertight fashion, then bone fl ap was posi-
tioned and fi xed. Th e patient was extubated immedi-
ately after the surgery, and was without any new neu-
rological defi cit (Figs. 2 and 3).
Th e tumor was composed of short strands or solid 
nests of round to slightly spindled endothelial cells with 
abundant glassy eosinophilic cytoplasm with well-de-
fi ned cell borders, and round to ovoid, bland, often ve-
sicular nuclei with small central nucleoli (Fig. 4). Th ese 
cells showed intracytoplasmic lumina containing eryth-
rocytes. Tumor cells were negative for CK7, CK20, 
PAX8, TTF1, CDX2, epithelial membrane antigen, 
glial fi brillary acidic protein, S100, and showed strong 
and uniform immunoreactivity for endothelium-specif-
ic markers CD31, CD34 and for ERG. Th ere were foci 
Fig. 4. (a) Microscopically, epithelioid-appearing cells were distributed in cords 
or nests. Th e tumor cells had oval or round nuclei and variably eosinophilic cytoplasm, 
and some contained cytoplasmic vacuoles. Some cells formed small intracellular 
lumina with occasional red cells included. Cellular pleomorphism was signifi cant, 
and rare mitotic fi gures were present; (b) immunohistochemically, the tumor was 
positive for anti-ERG (E26 oncogene homolog); (c) the tumor was strongly and 
diff usely positive for CD31; (d) immunohistochemically, the tumor was strongly 
and diff usely positive for panCK (AE1/AE3) (magnifi cation X100).
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of necrosis. Th e fi ndings of a tumor of endothelial cells 
showing a focally solid pattern of growth, histiocytoid 
cytology, and lacking aggressive features of angiosarco-
ma indicated a diagnosis of EHE.
After the surgery, the patient was discharged home 
in neurologically intact condition. Postoperative MRIs 
of the brain did not show any evidence of residual or 
recurrent tumor. Considering the new WHO classifi -
cation of the central nervous system (CNS) tumors 
(2016) and changing of tumor grading from grade I to 
grade III, the patient was called to discuss adjuvant 
therapy, which he rejected.
Discussion
Epithelioid hemangioendothelioma is an uncom-
mon tumor that accounts for 1% of all vascular tumors 
and the most common primary location of which is in 
soft tissues, bone, lung and liver. It is rarely located in-
tracranially, primarily within the skull base, dura, or 
brain parenchyma, accounting for <0.02% all brain tu-
mors1,2. Localization of EHE in the posterior fossa 
seems to be extremely rare according to a systematic 
review by Barger et al.3. In this work, 47 intracranial 
EHE cases are described, none located in the cerebel-
lum. Only 6 cases of EHE were located in the poste-
rior cranial fossa, outside of the cerebellum (Table 1)3. 
None was radically resected; fi ve were removed subto-
tally and biopsy was performed in one case. In addi-
tion, in our search of the English literature (PubMed 
and Google Scholar databases), no cerebellar location 
has been reported.
Epithelioid hemangioendothelioma is a tumor that 
is clinically and histologically similar to both benign 
hemangioma and angiosarcoma; it has some charac-
teristics of a malignant tumor, such as invasion, recur-
rence and metastasis. Concerning the 2016 WHO 
Classifi cation of Tumors of the CNS, EHE is classi-
fi ed as mesenchymal, non-meningothelial tumor grade 
III4. It is interesting that in the 2007 WHO classifi ca-
tion, EHE is classifi ed as grade I neoplasm. Th is new 
classifi cation changes drastically the postoperative on-
cologic treatment regarding adjuvant therapy.
Histologic diff erential diagnosis and characteristics 
of EHE
Diff erential diagnosis of brain EHE includes met-
astatic carcinoma, epithelioid sarcoma, chondroma 
and choroid meningioma4,6-9. Epithelioid angiosarco-
ma may also be considered in diff erential diagnosis in 
cases of EHE with increased nuclear atypia. Epitheli-
oid sarcoma (ES) is sometimes considered in diff eren-
tial diagnosis because of the immunophenotypic over-
lap. ES has strong keratin expression and EMA posi-
tivity, approximately 50% of ES are positive for CD34. 
EHE has a growth pattern of capillary sized channels 
lined by endothelial cells, with stroma rich in lympho-
cytes and histiocytes. Its cells contain relatively abun-
dant eosinophilic cytoplasm, which may be vacuolated. 
In general, the nuclei are round or occasionally indent-
ed or vesicular, and show only minor atypia. Mitoses 
and limited necrosis may be seen. Small intracytoplas-
mic lumina (blister cells) are seen, but well-formed 
vascular channels are typically absent. Immunohisto-
chemical studies (e.g., for CD31 and ERG) confi rm 
the endothelial nature of these tumors. Approximately 
90% of EHE harbor recurrent t(1;3)(p36;q25) translo-
cation, which results in WWTR1-CAMTA1 fusion10. 
Table 1. Reported cases of intracranial epithelioid hemangioendothelioma, partially or completely located in posterior 
cranial fossa








1 Chen et al., 1997 3/M Cervico-medullary Subtotal Chemo Tumor decrease (4 yrs)
2 Tamman et al., 1997 4/M Cerebellopontine angle Subtotal Radio Tumor stable (2 mo)
3 Rushing et al., 1998 38/F Clivus Biopsy Radio N/A
4 Watanabe et al., 2003 55/F Lower petroclival region Subtotal Radio Tumor stable 1 yr
5 Zheng et al., 2012 44/F Lower petroclival region Subtotal None Tumor stable 1.5 yrs




2 surgeries in 8 yrs
Chemo = chemotherapy; Radio = radiotherapy; N/A = not available
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A novel WWTR1-CAMTA1 gene fusion is a consis-
tent abnormality in EHE of diff erent anatomic 
sites11,12.
Hemangioendothelioma is characterized by myx-
oid and hyalinized stroma, and angiosarcoma by irregu-
lar vascular or sinusoid channels, atypical mitosis, solid 
growth pattern, and typically foci of necrosis are pres-
ent2,4-7, while chondroma and choroid meningioma are 
microscopically showing cords and nests of epithelioid 
cells and growth pattern with extracellular chondroid 
material4. Epithelioid sarcoma has a higher level of 
nuclear atypia and often develops in distal extremities, 
with round eosinophilic cells surrounding cores of ne-
crotic debris. Metastatic carcinoma has greater atypia 
and is positive for cytokeratins4. Defi nitive diagnosis 
of EHE is confi rmed with positive endothelial cell 
markers CD31, CD 34 and factor VII-associated anti-
gen, as in our case where the EHE was positive for 
CD31 and CD34, which confi rmed the diagno-
sis2,4,10-14. Another important characteristic and mo-
lecular marker of EHE is chromosomal translocation 
resulting in WWTR1-CAMTa fusion, which is 
unique for EHE, and can help confi rm EHE in over-
lapping cases7,13-17.
Treatment options
Treatment protocols for intracranial EHE are 
not well established because of its rare occurrence. 
Th e treatment of choice is complete excision of 
EHE1,7,10,11,18-24. In our case, complete surgical excision 
without any radiotherapy and chemotherapy was per-
formed. In all reported cases, approximately 60% of all 
EHE were completely removed, but none of those 
with cerebellar location1. Pre- and postoperative adju-
vant therapies are now recommended for EHE if 
complete resection is not possible because of the in-
vading nature of the tumor to local tissues due to vas-
cularity of EHE, where bleeding and blood loss can 
cause patient death, or in case of metastasis or multiple 
tumors1,6. Some authors recommended preoperative 
embolization of the lesion to prevent profuse bleed-
ing1. Experience with radiotherapy in the management 
of EHE is very poor, as it was used in only few cases to 
date. Zheng et al.1 report that only 13 patients under-
went radiotherapy for intracranial EHE and only one 
case for tumor bed after total removal1,6.
Given the possibility of higher radiotherapy mor-
bidity and the lack of strong data supporting it over 
chemotherapy, the latter is likely a better fi rst option 
for adjuvant treatment than radiation. However, no 
chemotherapeutic agent has been shown to consis-
tently infl uence tumor shrinkage but a number of 
those do seem to prevent further growth to a certain 
extent, albeit inconsistently. Traditionally, interferon 
alpha has been used, the rationale being that it inhibits 
endothelial growth and thus may be eff ective against a 
tumor derived from endothelial tissue25. A number of 
other antiangiogenic medications have also been uti-
lized. In a recent review of 36 patients with EHE 
treated with antiangiogenic therapy (thalidomide, le-
nalidomide, sorafenib, or bevacizumab alone or in 
combination), six patients experienced partial response, 
14 stable disease, and 16 progressive disease26. Radio-
therapy seems to have similar rates of success; out of 
seven patients in the literature with intracranial EHE 
who received adjuvant radiotherapy, one had tumor 
shrinkage, three had stable tumor, and three experi-
enced recurrent tumor growth and symptoms1,3. Some 
treatment options with chemotherapy may result in 
better outcome, especially for metastatic and multiple 
cases25,26.
It is important to note that our patient was oper-
ated in 2015 when the WHO classifi cation of CNS 
tumors from 2007 was used, according to which EHE 
was classifi ed as grade I. Considering the new WHO 
classifi cation from 2016, according to which the same 
tumor is now designated as malignant (grade III), the 
patient was called for an interview for additional ther-
apy, but he refused it. Interestingly, this tumor in this 
new calibration has changed drastically from benign 
grade I to malignant grade III. Th is should be consid-
ered in long-term follow up of EHE patients and neu-
rosurgeons should be aware of this.
Despite the new grading score and with limited ex-
perience with radio- and chemotherapy of intracranial 
EHE, gross total resection remains the treatment of 
choice. Adjuvant treatment should be considered, but 
long-term experience on larger patient population is 
lacking1. In our case, MRI at 2-year follow up showed 
that resection was complete without recurrence and no 
adjuvant treatment so far.
Conclusion
Epithelioid hemangioendothelioma is an uncom-
mon and rare primary intracranial vascular tumor. Th e 
localization of this tumor in the cerebellum has not 
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been described before; no radical tumor resection 
of this tumor has been accomplished so far in this 
 location. Histopathologic and immunohistochemical 
characteristics of the tumor are essential for the diag-
nosis of EHE. Complete surgical excision is a recom-
mended treatment, with scrutinized long-term follow 
up by MRI screening. Adjuvant treatment should be 
strongly considered despite the lack of experience with 
it. Neurosurgeons treating or following up EHE pa-
tients should be aware of the drastic change in its clas-
sifi cation from benign (WHO 2007) to malignant 
(WHO 2016).
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Sažetak
PRIMARNI EPITELOIDNI HEMANGIOENDOTELIOM U MALOM MOZGU: 
PRIKAZ SLUČAJA UZ OSVRT NA DRASTIČNU PROMJENU U KLASIFIKACIJI SZO
I. Omerhodžić, N. Bilalović, B. Rovčanin, B. Imširović, E. Suljić, A. Rotim i K. Arnautović
Epiteloidni hemangioendoteliom je rijedak vaskularni tumor mozga. Nastaje iz endotelnih stanica, obično u jetri, plući-
ma, kosti i mekom tkivu. Primarna lokalizacija ovoga tumora u intrakranijskom prostoru je veoma rijetka; samo je 47 sluča-
jeva opisano u literaturi. Ovaj tumor je isprva bio klasifi ciran kao gradus I (dobroćudan) u klasifi kaciji Svjetske zdravstvene 
organizacije (SZO) iz 2007. godine. U 2016. godini ovaj tumor je klasifi ciran kao gradus III (zloćudan). Autori opisuju prvi 
slučaj epiteloidnog hemangioendotelioma u malom mozgu kod muškog bolesnika. Izvršena je potpuna kirurška ekscizija. 
Adjuvantna terapija nije ordinirana. Nalaz magnetske rezonance 2 godine nakon operacije pokazao je da nema povratka 
 tumorske mase. Prema našem saznanju, ovo je prvi prikaz lokalizacije ovoga rijetkog tumora u malom mozgu. Također,  autori 
upućuju na drastičnu promjenu u klasifi kaciji epiteloidnog hemangioendotelioma od dobroćudnog tumora (SZO, 2007.) do 
zloćudnog (2016.), koja zasigurno mijenja poslijeoperacijski pristup i praćenje ove neoplazme mozga.
Ključne riječi: Hemangioendoteliom, epiteloidni; Moždani tumori; Svjetska zdravstvena organizacija; Mali mozak
